Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer

xlomafota13 shared this article with you from Inoreader Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer Via JAMA Otolaryngology–Head & Neck Surgery Current Issue This systematic review and meta-analysis assesses the efficacy and safety of neoadjuvant immunotherapy for resectable head and neck squamous cell carcinoma. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.